Greenwich LifeSciences (GLSI) Projected to Post Earnings on Tuesday
by Teresa Graham · The Cerbat GemGreenwich LifeSciences (NASDAQ:GLSI – Get Free Report) is expected to be releasing its results after the market closes on Tuesday, April 21st. Analysts expect Greenwich LifeSciences to post earnings of ($0.32) per share for the quarter.
Greenwich LifeSciences Price Performance
GLSI opened at $27.74 on Friday. Greenwich LifeSciences has a fifty-two week low of $7.78 and a fifty-two week high of $34.10. The firm’s fifty day moving average price is $25.67 and its two-hundred day moving average price is $18.78. The company has a market capitalization of $384.20 million, a P/E ratio of -19.00 and a beta of 1.53.
Institutional Investors Weigh In On Greenwich LifeSciences
Several institutional investors and hedge funds have recently made changes to their positions in GLSI. Bank of America Corp DE boosted its stake in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after purchasing an additional 1,322 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after purchasing an additional 3,168 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Greenwich LifeSciences by 109.6% in the 4th quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock valued at $165,000 after purchasing an additional 4,102 shares in the last quarter. Strs Ohio acquired a new stake in shares of Greenwich LifeSciences in the 1st quarter valued at $177,000. Finally, Jane Street Group LLC acquired a new stake in shares of Greenwich LifeSciences in the 4th quarter valued at $203,000. Institutional investors and hedge funds own 4.16% of the company’s stock.
Analyst Ratings Changes
A number of research firms have weighed in on GLSI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th. Finally, HC Wainwright lifted their price target on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 30th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $47.50.
View Our Latest Report on GLSI
About Greenwich LifeSciences
Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.
Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.